Global Health & Disease Outbreaks

Introduction

Global health and disease outbreaks constitute a critical subtopic within the Current Affairs syllabus for the WBCS examination. This domain examines the intersection of epidemiology, public policy, international cooperation, and national preparedness in the face of infectious disease threats that transcend borders. For a serious aspirant, mastering this area is not merely about memorising a list of viruses and vaccines; it requires understanding the structural logic of how the world detects, responds to, and prevents pandemics, and how India fits into that global architecture.

The WBCS examination has tested this subtopic with three questions across the 2020 and 2021 papers, focusing on factual recall of virus nomenclature (SARS‑CoV‑2), a specific discovery (Nipah virus antibodies in Mahabaleswar cave), and a vaccine introduction (India‑made typhoid vaccine). The questions are precise, often drawn from recent WHO announcements or Indian research breakthroughs. The level of difficulty is moderate—neither obscure nor trivial—demanding that the student stay current with global health news and understand the conceptual framework behind the facts.

This chapter will equip you with everything needed to ace such questions. We begin by building a rock‑solid foundation of core epidemiological and global health terms. Then we dive into four deep‑dive sections: the major disease outbreaks of the 21st century, the role of the World Health Organization (WHO) in global health security, India’s preparedness and response mechanisms, and the landscape of vaccine development and immunization. Each section is anchored in the official syllabus points—national events, international affairs, science & technology, government schemes, and defence & security—ensuring no tested or examinable area is left uncovered. We will then walk through the actual PYQs step by step, analyse trends, predict future question angles, highlight common traps, and provide memory aids for rapid recall. The final Quick Revision section condenses everything into a day‑before‑exam digest.

By the end of these notes, you will not only know the facts but also understand why they matter, how they connect, and how to apply them under exam pressure. Let us begin.

Core Concepts & Foundations

Before analysing specific outbreaks or policies, you must internalise the language of global health. Every term below will appear repeatedly in questions, news articles, and official documents. Read each definition carefully and return to this section whenever you encounter an unfamiliar word later in the chapter.

Pandemic: An epidemic that has spread over several countries or continents, usually affecting a large number of people. The key distinction from an epidemic is geographical breadth. COVID‑19, the 1918 influenza, and HIV/AIDS are classic pandemics.

Epidemic: A sudden increase in the number of cases of a disease above what is normally expected in a population in a specific area. For example, the 2014–2016 Ebola outbreak in West Africa was an epidemic that later threatened to become a pandemic but was contained.

Endemic: The constant presence of a disease or infectious agent within a given geographic area or population group. Malaria is endemic in many parts of India; it does not disappear but remains at a predictable baseline.

Outbreak: A term often used synonymously with epidemic, but it usually refers to a more limited geographic area or a sudden rise in cases of a disease that was previously absent or at low levels. A food‑borne illness cluster in a single town is an outbreak.

Zoonotic: A disease that can be transmitted from animals to humans. Approximately 60% of emerging infectious diseases are zoonotic. Examples include Nipah (bats to pigs to humans), Ebola (bats or primates to humans), and COVID‑19 (suspected bat origin via an intermediate host).

Reservoir: The long‑term host of a pathogen that does not necessarily show symptoms. For Nipah virus, fruit bats of the Pteropus genus are the natural reservoir. Understanding reservoirs is critical for predicting and preventing spillover events.

Vector: An organism that transmits a pathogen from a reservoir to a host. Mosquitoes are vectors for dengue, malaria, and Zika. Ticks transmit Lyme disease. In the context of Nipah, pigs acted as an amplifying host (not a vector) in the Malaysian outbreak.

Incubation period: The time between exposure to an infectious agent and the appearance of the first symptoms. For COVID‑19, the median incubation period is about 5 days (range 2–14 days). This period determines quarantine duration.

Basic reproduction number (R₀): The average number of secondary infections produced by one infected individual in a completely susceptible population. If R₀ > 1, the outbreak grows; if R₀ < 1, it declines. Measles has an R₀ of 12–18; COVID‑19’s original strain had an R₀ of about 2.5–3.

Herd immunity: The indirect protection from an infectious disease that occurs when a sufficient proportion of a population becomes immune (through vaccination or prior infection), thereby reducing the likelihood of spread to susceptible individuals. The threshold depends on R₀: for COVID‑19 (original strain), roughly 60–70% immunity was needed; for measles, >95%.

Vaccine efficacy: The percentage reduction in disease incidence among vaccinated individuals compared to unvaccinated individuals under controlled clinical trial conditions. For example, the Pfizer‑BioNTech mRNA vaccine showed 95% efficacy against symptomatic COVID‑19. Vaccine effectiveness measures real‑world performance.

WHO prequalification: A procedure by which the World Health Organization assesses the quality, safety, and efficacy of vaccines, medicines, and diagnostics for procurement by UN agencies and countries. Prequalification is a gold standard, especially for vaccines used in national immunization programmes. India’s Typbar TCV (typhoid conjugate vaccine) received WHO prequalification in 2017.

Emergency Use Authorization (EUA): A regulatory mechanism that allows the use of unapproved medical products during a public health emergency when no adequate, approved, or available alternatives exist. Many COVID‑19 vaccines were initially deployed under EUA.

International Health Regulations (IHR, 2005): A legally binding instrument for 196 countries, including all WHO Member States, that aims to prevent, protect against, control, and provide a public health response to the international spread of disease. It requires countries to report potential public health emergencies of international concern (PHEIC) and to build core surveillance and response capacities.

Public Health Emergency of International Concern (PHEIC): An extraordinary event declared by the WHO Director‑General under the IHR that constitutes a public health risk to other States through the international spread of disease and potentially requires a coordinated international response. Examples include the 2009 H1N1 pandemic, the 2014 Ebola outbreak, the 2016 Zika outbreak, and COVID‑19 (declared a PHEIC on 30 January 2020).

One Health: An integrated, unifying approach that recognizes the interconnection between people, animals, plants, and their shared environment. It is central to preventing zoonotic spillover and addressing antimicrobial resistance. India launched a National One Health Mission in 2022.

Comparison Table: Epidemic vs. Pandemic vs. Endemic

Understanding these definitions is the first step. Now we apply them to the real‑world events that have shaped global health and that WBCS has tested.

Major Global Disease Outbreaks of the 21st Century: Lessons from SARS to COVID‑19

The 21st century has witnessed an accelerating drumbeat of infectious disease outbreaks, each revealing gaps in global preparedness and spurring new frameworks for response. This section covers the most significant events, with special attention to those directly tested in WBCS (COVID‑19 and Nipah) and those likely to appear in future papers.

SARS (2003)

Severe Acute Respiratory Syndrome (SARS) was the first major pandemic of the 21st century. Caused by SARS‑CoV (a coronavirus), it emerged in Guangdong Province, China, in November 2002 and spread to 29 countries, infecting over 8,000 people with a case‑fatality rate of about 10%. The outbreak was contained by July 2003 through aggressive isolation, quarantine, and travel advisories. SARS demonstrated the speed of international spread via air travel and led to the revision of the International Health Regulations (IHR 2005). It also established the pattern of coronaviruses as a recurring threat—a lesson that proved prescient for COVID‑19.

H1N1 Influenza Pandemic (2009)

The 2009 H1N1 pandemic (initially called “swine flu”) was caused by a novel influenza A virus that combined genes from human, swine, and avian influenza viruses. It was first detected in Mexico and the United States and spread globally within weeks. The WHO declared a PHEIC in April 2009 and raised the pandemic alert level to Phase 6 (the highest) in June. Unlike seasonal flu, this virus disproportionately affected younger people. A vaccine was developed and deployed within six months. The pandemic officially ended in August 2010, with an estimated 151,700–575,400 deaths worldwide. This event tested the IHR framework and highlighted the challenge of vaccine equity—wealthy nations secured doses first, leaving low‑income countries waiting.

MERS (2012–present)

Middle East Respiratory Syndrome (MERS) is caused by MERS‑CoV, a coronavirus transmitted from dromedary camels to humans. First identified in Saudi Arabia in 2012, it has a high case‑fatality rate (~35%) but limited human‑to‑human transmission outside healthcare settings. Major outbreaks occurred in South Korea in 2015 (linked to a traveller from the Middle East) and in Saudi Arabia. MERS remains a sporadic threat, and no licensed vaccine is yet available. It reinforced the importance of infection control in hospitals and the role of animal reservoirs in emerging coronaviruses.

Ebola Virus Disease (2014–2016, 2018–2020)

The West African Ebola epidemic (2014–2016) was the largest in history, with over 28,000 cases and 11,000 deaths across Guinea, Sierra Leone, and Liberia. The virus, a filovirus, is transmitted through direct contact with bodily fluids. The outbreak overwhelmed weak health systems and exposed the catastrophic consequences of delayed international response. The WHO was criticised for its slow declaration of a PHEIC (August 2014, months after the outbreak began). This led to major reforms in WHO’s emergency response capacity, including the creation of the WHO Health Emergencies Programme. A second major outbreak in the Democratic Republic of the Congo (2018–2020) was controlled using an experimental vaccine (rVSV‑ZEBOV) that proved highly effective. Ebola remains a persistent threat in Central Africa.

Zika Virus (2015–2016)

Zika virus, a flavivirus transmitted primarily by Aedes mosquitoes, caused a major outbreak in Brazil in 2015, followed by rapid spread across the Americas. The virus was previously known to cause mild illness, but the 2015–2016 outbreak revealed a devastating link to microcephaly in newborns and Guillain‑Barré syndrome in adults. The WHO declared a PHEIC in February 2016. The outbreak highlighted the dangers of emerging vector‑borne diseases and the need for robust birth‑defect surveillance. No specific treatment or vaccine was available at the time; vector control and travel advisories were the main interventions.

COVID‑19 (2019–2023)

The COVID‑19 pandemic, caused by SARS‑CoV‑2 (tested in WBCS 2021), is the defining global health event of the 21st century. First detected in Wuhan, China, in December 2019, it spread to every continent within months. The WHO declared a PHEIC on 30 January 2020 and characterised it as a pandemic on 11 March 2020. As of 2023, over 770 million confirmed cases and 7 million deaths have been reported, though the true toll is likely higher.

Key features tested in WBCS:

• Official name of the virus: SARS‑CoV‑2 (not COVID‑19, which is the disease name). The WHO announced this name on 11 February 2020, following guidelines to avoid stigmatising geographic or animal references.
• Variants of concern: Alpha, Beta, Gamma, Delta, Omicron. The WHO adopted Greek letters to simplify public communication.
• Vaccines: Multiple platforms were developed in record time—mRNA (Pfizer‑BioNTech, Moderna), viral vector (Oxford‑AstraZeneca/Covishield, Sputnik V, Johnson & Johnson), inactivated (Sinovac, Covaxin), and protein subunit (Novavax). India’s Covaxin (Bharat Biotech) and Covishield (Serum Institute of India) were the mainstays of the domestic vaccination drive.
• Global response: COVAX facility (co‑led by WHO, GAVI, and CEPI) aimed to ensure equitable vaccine access. India’s “Vaccine Maitri” initiative exported doses to over 90 countries.
• India’s measures: Nationwide lockdown (March–May 2020), creation of the COVID‑19 National Task Force, expansion of hospital infrastructure under PM‑ABHIM (Pradhan Mantri Ayushman Bharat Health Infrastructure Mission), and the world’s largest vaccination campaign.

Nipah Virus (Recurrent Outbreaks)

Nipah virus (NiV) is a paramyxovirus that causes severe respiratory illness and encephalitis, with a case‑fatality rate of 40–75%. Its natural reservoir is fruit bats of the Pteropus genus. The first outbreak occurred in Malaysia and Singapore in 1998–1999, linked to pigs as amplifying hosts. Since then, recurrent outbreaks have occurred in Bangladesh and India (West Bengal in 2001, 2007; Kerala in 2018, 2019, 2021, 2023).

The WBCS 2021 question on the discovery of Nipah virus antibodies from Mahabaleswar cave is a landmark finding. In 2020, researchers from the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV) detected Nipah virus antibodies in bats captured from a cave in Mahabaleswar, Maharashtra. This was the first evidence of Nipah virus circulation in bats in the Western Ghats region, extending the known geographic range of the reservoir. The discovery underscored the importance of active surveillance in bat populations to predict and prevent future spillovers. India’s One Health approach, integrating human, animal, and environmental health, was strengthened after this finding.

Comparison Table: Key Outbreaks at a Glance

Key Insight: The pattern is clear—most emerging infectious diseases are zoonotic, with bats serving as a major reservoir. The 21st century has seen an acceleration of spillover events driven by deforestation, wildlife trade, and intensive livestock farming. Understanding this “One Health” nexus is essential for both exam preparation and real‑world prevention.

The World Health Organization and the Architecture of Global Health Security

The WHO is the directing and coordinating authority on international health within the United Nations system. For WBCS, questions often revolve around WHO’s naming conventions, declarations, and prequalification processes. This section builds a thorough understanding of the organisation’s role in outbreak response.

Structure and Governance

The WHO is headquartered in Geneva, Switzerland, with six regional offices: AFRO (Africa), AMRO (Americas), EMRO (Eastern Mediterranean), EURO (Europe), SEARO (South‑East Asia), and WPRO (Western Pacific). India falls under SEARO. The World Health Assembly (WHA) is the supreme decision‑making body, meeting annually in May. The Executive Board comprises 34 technically qualified members. The Director‑General (currently Dr Tedros Adhanom Ghebreyesus, since 2017) is the chief technical and administrative officer.

International Health Regulations (IHR 2005)

The IHR are the backbone of global outbreak surveillance. Key obligations for member states:

• Notify WHO of all events that may constitute a PHEIC within 24 hours.
• Maintain core capacities for surveillance, response, and reporting at points of entry (ports, airports, ground crossings).
• Cooperate with WHO‑led investigations and response missions.

The IHR were revised after the SARS outbreak to include a broader range of public health risks (chemical, radiological, and biological) and to give WHO the authority to use non‑governmental sources of information (e.g., media reports) to trigger investigations.

PHEIC Declarations

A PHEIC is declared by the WHO Director‑General on the advice of an Emergency Committee of independent experts. The criteria include:

• Seriousness and suddenness of the event.
• International spread risk.
• Need for coordinated international action.
• Potential for travel or trade restrictions.

Since 2005, PHEICs have been declared for: H1N1 (2009), polio (2014, ongoing), Ebola in West Africa (2014), Zika (2016), Ebola in DRC (2019), COVID‑19 (2020), and mpox (2022). The declaration triggers temporary recommendations (e.g., screening at airports, no travel bans) and mobilises resources.

WHO Naming of Diseases

The WHO introduced best practices for naming new human infectious diseases in 2015 to avoid stigmatising geographic locations, animals, or people. The name should consist of generic descriptive terms (e.g., “severe acute respiratory syndrome coronavirus 2”) and avoid terms like “Middle East,” “Spanish,” or “swine.” The official name for the COVID‑19 virus—SARS‑CoV‑2—follows this guideline. The disease itself is named COVID‑19 (Coronavirus Disease 2019). This distinction was tested in WBCS 2021.

WHO Prequalification and Emergency Use Listing

WHO prequalification (PQ) is a rigorous assessment of the quality, safety, and efficacy of vaccines, medicines, and diagnostics. PQ is required for procurement by UN agencies (e.g., UNICEF, PAHO) and many national governments. India’s Typbar TCV (typhoid conjugate vaccine) was prequalified in 2017, making it the first typhoid vaccine to achieve this status. It was subsequently introduced into routine immunization programmes in several countries, including Zimbabwe (2018) and later in India’s private sector. The WBCS 2020 question on the first country to introduce this vaccine likely refers to Zimbabwe, though the answer key was missing. The vaccine was developed by Bharat Biotech and is a key example of India’s contribution to global health.

During emergencies, WHO uses an Emergency Use Listing (EUL) procedure to expedite the availability of unlicensed vaccines, tests, and treatments. COVID‑19 vaccines (e.g., Pfizer, AstraZeneca, Covaxin) were listed under EUL.

Global Health Initiatives and India’s Role

India is a major player in global health governance. It is a founding member of WHO, a key contributor to the Global Fund to Fight AIDS, Tuberculosis and Malaria, and a leading supplier of generic medicines and vaccines (the “pharmacy of the world”). India’s Vaccine Maitri initiative during COVID‑19 exemplified its soft‑power diplomacy. The country also hosts the WHO Global Centre for Traditional Medicine in Jamnagar, Gujarat (inaugurated 2022).

Key Insight: For WBCS, focus on WHO’s naming conventions, PHEIC declarations, and prequalification milestones. Questions often test the difference between a virus name and a disease name, or the significance of a WHO decision (e.g., prequalification of an Indian vaccine).

India’s Preparedness and Response: From Nipah to COVID‑19

India’s experience with disease outbreaks has shaped a robust, though still evolving, public health infrastructure. This section covers the institutional mechanisms, key programmes, and recent initiatives that are directly relevant to the WBCS syllabus points on national events and government schemes.

Institutional Framework

• Ministry of Health and Family Welfare (MoHFW): The nodal ministry for health policy, disease surveillance, and outbreak response.
• National Centre for Disease Control (NCDC): Under MoHFW, NCDC is the apex institution for epidemiological surveillance and outbreak investigation. It operates the Integrated Disease Surveillance Programme (IDSP) , which collects real‑time data on 33 epidemic‑prone diseases from district, state, and national levels.
• Indian Council of Medical Research (ICMR): The apex body for biomedical research. ICMR’s National Institute of Virology (NIV) in Pune is the lead laboratory for viral diagnostics and research. NIV played a central role in isolating SARS‑CoV‑2, developing diagnostic kits, and detecting Nipah antibodies in Mahabaleswar bats.
• National Health Mission (NHM): Comprising the National Rural Health Mission (NRHM) and National Urban Health Mission (NUHM), NHM supports state health systems, including disease surveillance and outbreak response at the grassroots.
• Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PM‑ABHIM): Launched in 2021 with a budget of ₹64,180 crore, PM‑ABHIM aims to strengthen India’s health infrastructure for pandemic preparedness. Key components include establishing Health Emergency Operation Centres (HEOCs) at all levels, expanding laboratory networks, and setting up Critical Care Hospital Blocks in 730 districts.

Key Outbreak Responses

Nipah in Kerala (2018, 2019, 2021, 2023): Kerala’s response to Nipah outbreaks has been widely praised. The state’s robust public health system, rapid contact tracing, isolation protocols, and community engagement contained each outbreak to a small number of cases. The 2018 outbreak in Kozhikode district was the first in India since 2007. The index case was a fruit bat‑contaminated well. The state government, with support from ICMR‑NIV, deployed rapid response teams, established a dedicated treatment protocol, and used the antiviral drug Ribavirin (though its efficacy is debated). The discovery of Nipah antibodies in bats from Mahabaleswar cave (2020) by ICMR‑NIV researchers highlighted the need for expanded surveillance across the Western Ghats.

COVID‑19 (2020–2023): India’s response evolved through several phases:

• Lockdown (March–May 2020): One of the world’s strictest lockdowns, imposed at 4 hours’ notice, aimed at flattening the curve.
• Testing and surveillance: India scaled up testing from a few thousand per day to over 2 million per day. The Indian Council of Medical Research approved multiple RT‑PCR kits and rapid antigen tests.
• Vaccination drive: Launched on 16 January 2021, initially for healthcare workers, then phased to cover all adults by May 2021. Over 2.2 billion doses were administered by 2023, making it the world’s largest vaccination campaign. Covaxin (inactivated whole‑virion) and Covishield (viral vector, manufactured by Serum Institute under licence from AstraZeneca) were the two main vaccines.
• Second wave (April–May 2021): The Delta variant caused a devastating surge, overwhelming hospitals and leading to oxygen shortages. The crisis prompted reforms in medical oxygen production and distribution, and accelerated the expansion of hospital beds under PM‑ABHIM.
• Lessons learned: India strengthened its National Pharmaceutical Pricing Authority to control prices of essential medicines, and established a National Task Force for COVID‑19 management. The pandemic also catalysed the National Digital Health Mission (now Ayushman Bharat Digital Mission) for electronic health records.

Government Schemes and Programmes Relevant to Health Security

The WBCS syllabus explicitly includes “Government schemes & programmes.” The following are directly tied to disease outbreaks:

• Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB‑PMJAY): The world’s largest health insurance scheme, providing ₹5 lakh per family per year for secondary and tertiary care hospitalisation. It covers over 10 crore poor and vulnerable families.
• Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PM‑ABHIM): As above, this is the flagship scheme for pandemic preparedness.
• National One Health Mission: Launched in 2022 under the Prime Minister’s Science, Technology and Innovation Advisory Council (PM‑STIAC) . It coordinates human, animal, and environmental health surveillance to prevent zoonotic outbreaks.
• Integrated Health Information Platform (IHIP): An upgraded version of IDSP, providing real‑time, case‑based data for 33 diseases.
• Mission COVID Suraksha: A ₹900‑crore scheme to accelerate indigenous vaccine development, which supported Covaxin and other candidates.

Key Insight: WBCS questions on India’s response often test specific scheme names, the year of launch, or the institution responsible (e.g., ICMR‑NIV for Nipah antibody discovery). Be precise with names and dates.

Vaccine Development and Immunization: Breakthroughs and Challenges

Vaccines are the most powerful tool for preventing infectious disease outbreaks. This section covers the science of vaccine development, notable Indian vaccines, and global immunization initiatives—all within the WBCS syllabus’s “Science, technology & innovation” and “International affairs” domains.

Types of Vaccines

India’s Vaccine Success Stories

• Typbar TCV (Typhoid Conjugate Vaccine): Developed by Bharat Biotech International Limited, Typbar TCV is the world’s first typhoid conjugate vaccine to receive WHO prequalification (2017). It is a single‑dose vaccine that provides long‑lasting protection against typhoid fever, a major public health problem in India and other endemic countries. The vaccine was first introduced into routine immunization in Zimbabwe in 2018 (the WBCS 2020 question likely referred to this, though the answer key was missing). In India, it is available in the private market and is being considered for inclusion in the Universal Immunization Programme (UIP).
• Covaxin (BBV152): India’s first indigenous COVID‑19 vaccine, developed by Bharat Biotech in collaboration with ICMR and NIV. It is an inactivated whole‑virion vaccine, adjuvanted with Alhydroxiquim‑II. Covaxin received WHO Emergency Use Listing in November 2021.
• Covishield: The Indian version of the Oxford‑AstraZeneca vaccine, manufactured by the Serum Institute of India (SII) , the world’s largest vaccine manufacturer by volume. Covishield was the backbone of India’s vaccination drive and was exported to over 90 countries.
• Zydus Cadila’s ZyCoV‑D: The world’s first DNA‑based COVID‑19 vaccine, approved in India in August 2021 for adults and children aged 12 years and above. It is needle‑free, administered via a three‑dose regimen using a jet injector.

Global Immunization Initiatives

• COVAX: Co‑led by WHO, GAVI (the Vaccine Alliance), and CEPI (Coalition for Epidemic Preparedness Innovations), COVAX aimed to deliver 2 billion doses of COVID‑19 vaccines to low‑ and middle‑income countries by the end of 2021. India’s SII was a major supplier.
• GAVI: A public‑private partnership that has vaccinated over 1 billion children against deadly diseases. India is a major recipient of GAVI support for vaccines like pentavalent, rotavirus, and pneumococcal.
• Global Polio Eradication Initiative (GPEI): India was declared polio‑free in 2014, a landmark achievement driven by the Pulse Polio programme. The last case of wild poliovirus in India was reported in 2011.
• Mission Indradhanush: India’s flagship immunization programme, launched in 2014, aiming to achieve 90% full immunization coverage by 2020. It targets unvaccinated and partially vaccinated children and pregnant women.

Key Insight: For WBCS, remember the distinction between vaccine platforms (especially inactivated vs. viral vector vs. mRNA), the names of Indian vaccines and their developers, and the significance of WHO prequalification. The Typbar TCV story is a strong candidate for a future question.

Worked Examples & Applications

We now apply the concepts learned to the actual PYQs. For each question, we walk through the reasoning step by step, explaining why each distractor is wrong and why the correct answer is right.

Example 1 — WBCS 2021

Question: According to WHO, the official name of the virus responsible for Covid-19 disease is

Choices students saw:

• Covid-19
• nCovid-19
• Corona Virus
• SARS-CoV-2

Walkthrough:

1. What the question is testing: The distinction between the name of the disease (COVID‑19) and the name of the virus that causes it (SARS‑CoV‑2). The WHO announced both names on 11 February 2020, following guidelines to avoid stigmatising terms.
2. Why each wrong choice is wrong:
   • Covid-19: This is the name of the disease (Coronavirus Disease 2019), not the virus. The question explicitly asks for the “name of the virus.”
   • nCovid-19: This was an early provisional term used by some media (novel coronavirus disease 2019), but it was never the official WHO name for the virus. It conflates the disease and the virus.
   • Corona Virus: This is a family of viruses (Coronaviridae), not a specific virus. SARS‑CoV‑2 is one member of this family.
3. Why the correct choice is right: SARS‑CoV‑2 (Severe Acute Respiratory Syndrome Coronavirus 2) is the official name given by the International Committee on Taxonomy of Viruses (ICTV) and endorsed by WHO. It reflects the virus’s genetic similarity to SARS‑CoV (the 2003 SARS virus) and its classification as a coronavirus.

Correct answer: SARS‑CoV‑2

Takeaway: Always distinguish between the disease name (COVID‑19) and the pathogen name (SARS‑CoV‑2). This distinction is a favourite of examiners.

Example 2 — WBCS 2021

Question: Researchers have discovered recently antibody of which virus from Mahabaleswar cave?

Choices students saw:

• Ebola
• Covid 19
• Zika
• Nipah

Walkthrough:

1. What the question is testing: Knowledge of a specific research finding in India—the detection of Nipah virus antibodies in bats from Mahabaleswar cave, Maharashtra, by ICMR‑NIV scientists in 2020.
2. Why each wrong choice is wrong:
   • Ebola: Ebola virus is endemic in Central and West Africa, not in India. No Ebola antibodies have been reported from Indian bat populations.
   • Covid 19: COVID‑19 is caused by SARS‑CoV‑2, which is believed to have originated in bats in China. While Indian bats have been tested for SARS‑CoV‑2‑related coronaviruses, the Mahabaleswar cave discovery specifically involved Nipah virus.
   • Zika: Zika virus is transmitted by mosquitoes, not bats. Its reservoir is primarily non‑human primates and possibly rodents. No Zika antibodies have been reported from Mahabaleswar.
3. Why the correct choice is right: In 2020, a team from ICMR‑NIV collected bat samples from a cave in Mahabaleswar, Satara district, Maharashtra, and detected antibodies against Nipah virus. This was the first evidence of Nipah virus circulation in bats in the Western Ghats, extending the known geographic range of the reservoir.

Correct answer: Nipah

Takeaway: This question tests awareness of recent Indian research in virology. Pay attention to news about ICMR‑NIV discoveries, especially those involving zoonotic viruses and bat surveillance.

Example 3 — WBCS 2020

Question: India made typhoid vaccine, approved by WHO was first introduced in the country

Choices students saw:

• Nepal
• Bangladesh
• Myanmar
• Pakistan

Walkthrough: Note: The original answer key was missing. Based on available evidence, the correct answer is likely Zimbabwe, but that option was not given. The question as printed in the WBCS paper may have had a different set of options or the answer key may have been erroneous. For teaching purposes, we will explain the correct fact and analyse the distractors as they appear.

1. What the question is testing: Knowledge of the first country to introduce the WHO‑prequalified Indian typhoid conjugate vaccine (Typbar TCV) into routine immunization.
2. Why each wrong choice is wrong (assuming the correct answer is not among them):
   • Nepal: Nepal has a high typhoid burden and later introduced the vaccine, but it was not the first.
   • Bangladesh: Similarly, Bangladesh introduced the vaccine in some pilot areas but not as the first country.
   • Myanmar: No record of being the first.
   • Pakistan: Pakistan has used typhoid conjugate vaccines in outbreak response, but not as the first routine introduction.
3. Why the correct choice (Zimbabwe) is right: In 2018, Zimbabwe became the first country to introduce Typbar TCV into its routine childhood immunization programme, with support from GAVI. This was a landmark event for global typhoid control.

Correct answer: Zimbabwe (though not listed in the given choices; the question may have had a different set or the answer key may have been misprinted).

Takeaway: When a PYQ has a missing or questionable answer key, focus on learning the correct historical fact. For WBCS, be prepared for questions on the first country to introduce a specific Indian vaccine. Zimbabwe is the correct answer for Typbar TCV.

PYQ Trends & Patterns

Analysing the three PYQs (two usable, one with missing key) reveals a clear pattern:

• Question type: All three are factual recall questions. They test specific pieces of information: a WHO‑announced name, a research discovery, and a vaccine introduction milestone. No analytical or comparative questions have appeared yet.
• Difficulty level: Moderate. The facts are not obscure but require the student to have read recent news or official WHO/ICMR announcements. The Nipah antibody question, for instance, was widely reported in Indian media in 2020.
• Topics covered: Virus nomenclature (COVID‑19), zoonotic disease surveillance (Nipah), and vaccine policy (typhoid). All three fall under the broader umbrella of “global health & disease outbreaks” but each touches a different sub‑area: WHO guidelines, Indian research, and global immunization.
• Year distribution: Two questions from 2021, one from 2020. This suggests that the subtopic is tested regularly, likely with one question per paper.
• Future trajectory: Given that the three questions are all factual, the next WBCS paper may continue this pattern or introduce a slightly more analytical flavour—for example, matching outbreaks to their reservoirs, or sequencing events in a pandemic timeline. The syllabus’s inclusion of “International affairs” and “Science & technology” also opens the door for questions on WHO reforms, COVAX, or India’s vaccine diplomacy.

Key takeaway for preparation: Focus on recent (last 3–5 years) WHO announcements, ICMR discoveries, and vaccine milestones. Read the “Health” section of The Hindu or Indian Express regularly. Maintain a fact‑sheet of key names, dates, and organisations.

What Else Could Be Asked

Based on the patterns in the three PYQs and the official syllabus scope, we can forecast several plausible question angles. The table below presents concrete predictions, each anchored in the tested material.

Common Mistakes & Traps

Students often lose marks on this subtopic due to easily avoidable confusions. Here are the most frequent traps:

• Confusing the virus name with the disease name. The classic error: writing “COVID‑19” when the question asks for the virus. Always check whether the question says “virus” or “disease.” SARS‑CoV‑2 is the virus; COVID‑19 is the disease.
• Thinking “nCovid‑19” is an official name. It was never official. The WHO rejected it because it was imprecise and could cause confusion with other novel coronaviruses.
• Assuming all coronaviruses are the same. SARS‑CoV (2003), MERS‑CoV (2012), and SARS‑CoV‑2 (2019) are distinct viruses. Mixing up their years or reservoirs is a common error.
• Misattributing the Mahabaleswar discovery. Some students think the antibodies were for COVID‑19 or Ebola. The discovery was specifically for Nipah virus, and it was made by ICMR‑NIV, not a private lab.
• Forgetting the reservoir for Nipah. Many students remember that bats are involved but confuse the genus (Pteropus fruit bats) with insectivorous bats. The correct reservoir is fruit bats.
• Believing that WHO “prequalification” and “emergency use listing” are the same. Prequalification is a routine quality assessment for procurement; EUL is an emergency pathway. Typbar TCV received prequalification; COVID‑19 vaccines received EUL.
• Mixing up the first country to introduce Typbar TCV. If the question appears again, the correct answer is Zimbabwe, not any of India’s neighbours. The distractors in the 2020 question (Nepal, Bangladesh, Myanmar, Pakistan) were all plausible but incorrect.
• Overlooking the year of the PHEIC declaration for COVID‑19. It was 30 January 2020, not March 2020 (when the pandemic was declared). Many students conflate the two dates.

Memory Aids & Mnemonics

Mnemonic 1: “C‑SHMEZN” for Major 21st Century Outbreaks

Name: The “C‑SHMEZN” chain

The mnemonic: Think of the word “C‑SHMEZN” (pronounced “see‑shmeh‑zen”). Each letter stands for a major outbreak in chronological order:

• C – COVID‑19 (2019)
• S – SARS (2002–2003)
• H – H1N1 (2009)
• M – MERS (2012)
• E – Ebola (2014–2016)
• Z – Zika (2015–2016)
• N – Nipah (1998–present, but recurrent)

What it unlocks: The sequence of major outbreaks and their approximate years. To recall the year for each, associate the letter with a key fact: SARS was first (2002–2003), H1N1 was 2009 (the year of the swine flu panic), MERS emerged in 2012 (the year after the Arab Spring), Ebola in 2014 (the year of the West Africa crisis), Zika in 2015–2016 (linked to the Rio Olympics), Nipah is ongoing (remember the Mahabaleswar discovery in 2020).

Worked example: If a question asks “Which outbreak occurred in 2012?”, you run through C‑SHMEZN: C (COVID‑19, 2019), S (SARS, 2002–2003), H (H1N1, 2009), M (MERS, 2012). Answer: MERS.

Mnemonic 2: “All Big Gorillas Dance Often” for COVID‑19 Variants of Concern

Name: The “ABGDO” mnemonic

The mnemonic: “All Big Gorillas Dance Often” – the first letters spell A, B, G, D, O, which correspond to the WHO Greek‑letter names for the first five variants of concern:

• A – Alpha (first identified in the UK)
• B – Beta (South Africa)
• G – Gamma (Brazil)
• D – Delta (India)
• O – Omicron (multiple countries, late 2021)

What it unlocks: The sequence of COVID‑19 variants of concern as designated by WHO. It helps recall both the names and the order of emergence. Note that after Omicron, WHO stopped naming new variants with Greek letters (using “Omicron sublineages” instead).

Worked example: If a question asks “Which variant was first identified in India?”, you recall the mnemonic: A, B, G, D, O – Delta is the fourth letter, and Delta was first detected in India in late 2020. Answer: Delta.

Quick Revision

Introduction

• Global health & disease outbreaks is a high‑yield Current Affairs subtopic for WBCS.
• Three PYQs from 2020–2021: virus nomenclature (SARS‑CoV‑2), Nipah antibody discovery, typhoid vaccine introduction.
• Requires factual recall of recent WHO/ICMR announcements and understanding of epidemiological concepts.

Core Concepts & Foundations

• Key terms: pandemic, epidemic, endemic, outbreak, zoonotic, reservoir, vector, incubation period, R₀, herd immunity, vaccine efficacy, WHO prequalification, EUA, IHR, PHEIC, One Health.
• All definitions must be memorised with examples.

Major Global Disease Outbreaks

• SARS (2003): SARS‑CoV, 10% CFR, contained by July 2003.
• H1N1 (2009): Swine flu, PHEIC, vaccine developed in 6 months.
• MERS (2012–present): MERS‑CoV, camels, 35% CFR, no vaccine.
• Ebola (2014–2016): West Africa, 11,000 deaths, led to WHO reforms.
• Zika (2015–2016): Microcephaly link, vector‑borne, no vaccine.
• COVID‑19 (2019–2023): SARS‑CoV‑2, PHEIC 30 Jan 2020, pandemic 11 Mar 2020.
• Nipah (1998–present): Fruit bat reservoir, high CFR, recurrent in India (Kerala).

WHO and Global Health Security

• WHO structure: Geneva HQ, 6 regional offices, WHA, Executive Board, Director‑General.
• IHR 2005: Legally binding, requires notification of PHEIC within 24 hours.
• PHEIC declarations: H1N1, polio, Ebola (2014 & 2019), Zika, COVID‑19, mpox.
• Naming conventions: Avoid geographic/animal terms; SARS‑CoV‑2 and COVID‑19 are distinct.
• Prequalification vs. EUL: Typbar TCV prequalified 2017; COVID‑19 vaccines under EUL.

India’s Preparedness and Response

• Institutions: MoHFW, NCDC, IDSP, ICMR‑NIV, NHM, PM‑ABHIM.
• Nipah response: Kerala’s containment model, Ribavirin, bat surveillance.
• COVID‑19 response: Lockdown, testing scale‑up, Covaxin & Covishield, world’s largest vaccination drive.
• Schemes: Ayushman Bharat (AB‑PMJAY), PM‑ABHIM, National One Health Mission, Mission Indradhanush.

Vaccine Development

• Platforms: Inactivated, live attenuated, viral vector, mRNA, protein subunit, conjugate.
• Indian vaccines: Typbar TCV (Bharat Biotech, WHO‑prequalified), Covaxin (inactivated), Covishield (viral vector), ZyCoV‑D (DNA).
• Global initiatives: COVAX, GAVI, GPEI.

Worked Examples

• PYQ 2021 (virus name): SARS‑CoV‑2, not COVID‑19.
• PYQ 2021 (Mahabaleswar): Nipah virus antibodies discovered by ICMR‑NIV.
• PYQ 2020 (typhoid vaccine): Typbar TCV first introduced in Zimbabwe (2018).

PYQ Trends

• Factual recall, moderate difficulty, one question per paper.
• Topics: WHO nomenclature, Indian research, vaccine milestones.

What Else Could Be Asked

• Reservoir of Nipah, disease name for SARS‑CoV‑2, manufacturer of Typbar TCV, COVAX, chronological order of outbreaks, institution behind Mahabaleswar discovery, difference between PHEIC and pandemic.

Common Mistakes

• Virus vs. disease name confusion.
• Mixing up coronaviruses (SARS, MERS, SARS‑CoV‑2).
• Forgetting Nipah reservoir (fruit bats).
• Confusing prequalification with EUL.
• Wrong first country for Typbar TCV (Zimbabwe, not neighbours).

Memory Aids

• “C‑SHMEZN” for outbreak sequence: COVID‑19, SARS, H1N1, MERS, Ebola, Zika, Nipah.
• “All Big Gorillas Dance Often” (ABGDO) for COVID‑19 variants: Alpha, Beta, Gamma, Delta, Omicron.